|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1991-5-14
|
|
pubmed:abstractText |
The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0167-6997
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
397-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:2084074-Adult,
pubmed-meshheading:2084074-Aged,
pubmed-meshheading:2084074-Antineoplastic Agents,
pubmed-meshheading:2084074-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2084074-Breast Neoplasms,
pubmed-meshheading:2084074-Drug Evaluation,
pubmed-meshheading:2084074-Drugs, Investigational,
pubmed-meshheading:2084074-Female,
pubmed-meshheading:2084074-Humans,
pubmed-meshheading:2084074-Indazoles,
pubmed-meshheading:2084074-Middle Aged,
pubmed-meshheading:2084074-Neoplasm Metastasis
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
|
|
pubmed:affiliation |
University of Wisconsin Clinical Cancer Center, Madison 53792.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
